Autoimmune Myasthenia Gravis (MG) is a autoimmune neuromuscular disease that causes defective neuromuscular transmission of electrical impulses, weakening muscles. Myasthenia Gravis is a chronic disorder where the connection between the nerve and the muscle is interrupted. Facial muscles such as eye and eyelids, facial expression and swallowing are commonly affected by the disorder. Medications, immunosuppressives, and occasional tymectomies are effective therapies for autoimmune myasthenia gravis. Autoimmune Myasthenia Gravis can be caused experimentally through the injection of purified neuromuscular junction acetylcholine receptors (AChR) and is frequently used to study MG. The process of inducing Myasthenia Gravis from patients to mice is referred to as passive transfer.
Experimental Autoimmune Myasthenia Gravis, Passive Transfer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Experimental Autoimmune Myasthenia Gravis, Passive Transfer below!
For more information on how to use Laverne, please read the How to Guide.
We have 441 products for the study of Experimental Autoimmune Myasthenia Gravis, Passive Transfer that can be applied to Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Experimental Autoimmune Myasthenia Gravis, Passive Transfer is also known as Passive Transfer Experimental Autoimmune Myasthenia Gravis.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.